VIRIDIAN PHARMA LIMITED
Get an alert when VIRIDIAN PHARMA LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-11-08 (in 6mo)
Last made up 2025-10-25
Watchouts
None on the register
Cash
£10K
-28.6% vs 2023
Net assets
£331K
+237.8% vs 2023
Employees
—
Average over period
Profit before tax
£311K
+220.6% vs 2023
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £2,496,000 | £8,801,000 | |
| Operating profit | £97,000 | £311,000 | |
| Profit before tax | £97,000 | £311,000 | |
| Net profit | £97,000 | £233,000 | |
| Cash | £14,000 | £10,000 | |
| Total assets less current liabilities | — | — | |
| Net assets | £98,000 | £331,000 | |
| Equity | £98,000 | £331,000 | |
| Average employees | — | — | |
| Wages | — | — | |
| Directors' remuneration | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+252.6%
£2,496,000 £8,801,000
-
Cash
-28.6%
£14,000 £10,000
-
Net assets
+237.8%
£98,000 £331,000
-
Employees
—
Not reported
-
Operating profit
+220.6%
£97,000 £311,000
-
Profit before tax
+220.6%
£97,000 £311,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 3.9% | 3.5% | |
| Net margin | 3.9% | 2.6% | |
| Current ratio | 1.04x | 1.12x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- VIRIDIAN PHARMA LIMITED 2002-06-11 → present
- PEARLLINK LIMITED 2002-03-20 → 2002-06-11
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Grant Thornton UK LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“To support the directors' assessment of the Company as a going concern, the Company undertakes regular forecasting of financial performance and cash flows. The approach to forecasting considers sensitivities around long term trading assumptions and the availability of funding and continued support from fellow Group entities. The directors have considered the financial position of the company at 31 December 2024 and the projected cash flows and financial performance of the company for the 12 months from the date of approval of these financial statements. The directors have also taken action to ensure that appropriate cash resources are available to fund the company's operations. Therefore, the directors consider, after making appropriate enquiries, that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
5 active · 16 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| RUYANT, Foucauld | Secretary | 2024-09-30 | — | — |
| DE ULTRA DE SOUSA BARCELOS, Bruno | Director | 2023-01-17 | Aug 1973 | Portuguese |
| LASSERRE, Xavier Pierre Christian | Director | 2023-06-26 | Apr 1972 | French |
| MEHRAI, Alexander | Director | 2026-03-30 | Jun 1975 | British |
| RUYANT, Foucauld | Director | 2024-09-30 | Oct 1975 | French |
Show 16 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| LANNING, Michael George | Secretary | 2002-05-20 | 2002-10-04 |
| SMITH, Gillian Dawn | Secretary | 2002-10-04 | 2016-07-01 |
| SWIFT INCORPORATIONS LIMITED | Corporate Nominee Secretary | 2002-03-20 | 2002-05-20 |
| BOVOLENTA, Andrea | Director | 2024-03-01 | 2024-06-05 |
| CLARK, Michael Leslie | Director | 2016-07-01 | 2017-02-28 |
| DELUARD, Bertrand | Director | 2019-03-11 | 2022-09-13 |
| GROVER, Jason | Director | 2016-07-01 | 2017-02-28 |
| HARRIS, Michael Christopher James | Director | 2016-07-01 | 2019-01-01 |
| JOANNESSE, Roseline Georgette | Director | 2017-02-28 | 2019-03-11 |
| LANNING, Michael George | Director | 2002-05-20 | 2016-07-01 |
| MONIN, Jean Bernard Claude | Director | 2022-11-01 | 2023-06-26 |
| POW, David | Director | 2002-05-20 | 2002-05-21 |
| ROCKLEY, Timothy Joseph | Director | 2002-10-04 | 2016-07-01 |
| SCHMIDT, Emmanuel | Director | 2019-03-11 | 2022-12-31 |
| SMITH, Julian Craig | Director | 2002-10-04 | 2016-07-01 |
| INSTANT COMPANIES LIMITED | Corporate Nominee Director | 2002-03-20 | 2002-05-20 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Orphea Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2023-08-30 | Active |
| Macarthys Laboratories Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors, Significant influence | 2016-07-01 | Ceased 2023-08-30 |
Filing timeline
Last 20 of 112 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-03-31 | AP01 | officers | Appoint person director company with name date | |
| 2025-10-28 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-09-22 | AA | accounts | Accounts with accounts type full | |
| 2024-12-12 | AA | accounts | Accounts with accounts type full | |
| 2024-10-30 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-17 | AP03 | officers | Appoint person secretary company with name date | |
| 2024-10-17 | AP01 | officers | Appoint person director company with name date | |
| 2024-10-17 | TM01 | officers | Termination director company with name termination date | |
| 2024-03-01 | AP01 | officers | Appoint person director company with name date | |
| 2023-10-30 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-10-03 | AA | accounts | Accounts with accounts type dormant | |
| 2023-09-01 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2023-09-01 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2023-07-10 | AP01 | officers | Appoint person director company with name date | |
| 2023-07-10 | TM01 | officers | Termination director company with name termination date | |
| 2023-05-10 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-01-27 | AP01 | officers | Appoint person director company with name date | |
| 2023-01-27 | TM01 | officers | Termination director company with name termination date | |
| 2022-12-07 | AP01 | officers | Appoint person director company with name date | |
| 2022-09-23 | TM01 | officers | Termination director company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.